Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.83)
# 405
Out of 4,334 analysts
79
Total ratings
76.9%
Success rate
40.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintained: Buy | $21 | $13.53 | +55.21% | 9 | May 19, 2026 | |
| CELC Celcuity | Rated: Buy | $150 → $183 | $138.23 | +32.39% | 4 | May 15, 2026 | |
| ZNTL Zentalis Pharmaceuticals | Rated: Hold | $5 | $4.06 | +23.15% | 1 | May 13, 2026 | |
| GMAB Genmab | Maintained: Buy | $40 | $26.88 | +48.84% | 4 | May 9, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $33 → $34 | $25.61 | +32.76% | 5 | May 8, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $167 | $151.56 | +10.19% | 9 | May 7, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintained: Buy | $53 → $57 | $53.24 | +7.06% | 14 | Apr 29, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $44 → $48 | $29.10 | +64.95% | 5 | Apr 14, 2026 | |
| IMCR Immunocore Holdings | Maintained: Buy | $60 | $28.83 | +108.12% | 3 | Apr 14, 2026 | |
| NUVL Nuvalent | Rated: Buy | $116 | $102.12 | +13.59% | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $11 → $16 | $21.68 | -26.20% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $27 | $25.57 | +5.59% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $30 → $23 | $23.43 | -1.84% | 8 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27 | $11.31 | +138.73% | 6 | Oct 23, 2025 |
Relay Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $21
Current: $13.53
Upside: +55.21%
Celcuity
May 15, 2026
Rated: Buy
Price Target: $150 → $183
Current: $138.23
Upside: +32.39%
Zentalis Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $5
Current: $4.06
Upside: +23.15%
Genmab
May 9, 2026
Maintained: Buy
Price Target: $40
Current: $26.88
Upside: +48.84%
Zymeworks
May 8, 2026
Maintained: Buy
Price Target: $33 → $34
Current: $25.61
Upside: +32.76%
Revolution Medicines
May 7, 2026
Maintained: Buy
Price Target: $167
Current: $151.56
Upside: +10.19%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintained: Buy
Price Target: $53 → $57
Current: $53.24
Upside: +7.06%
IDEAYA Biosciences
Apr 14, 2026
Maintained: Buy
Price Target: $44 → $48
Current: $29.10
Upside: +64.95%
Immunocore Holdings
Apr 14, 2026
Maintained: Buy
Price Target: $60
Current: $28.83
Upside: +108.12%
Nuvalent
Apr 2, 2026
Rated: Buy
Price Target: $116
Current: $102.12
Upside: +13.59%
Apr 1, 2026
Rated: Hold
Price Target: $11 → $16
Current: $21.68
Upside: -26.20%
Mar 24, 2026
Upgraded: Buy
Price Target: $8 → $27
Current: $25.57
Upside: +5.59%
Feb 12, 2026
Downgraded: Hold
Price Target: $30 → $23
Current: $23.43
Upside: -1.84%
Oct 23, 2025
Maintained: Buy
Price Target: $27
Current: $11.31
Upside: +138.73%